Literature DB >> 31436583

Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types?

Franck J Barrat1,2,3, Theresa T Lu1,4,3.   

Abstract

PURPOSE OF REVIEW: The role of type I IFNs (IFN-I) in the promotion of autoimmunity has been well established. However, its role in the skin fibrosis of systemic sclerosis (SSc) is less clear. IFN-I can participate to tissue repair, and, here, we will consider the extent to which IFN-I's role in SSc skin fibrosis may reflect in part IFN-I functions during wound healing. RECENT
FINDINGS: Studies are beginning to delineate whether IFN-I has a protective or pathogenic role and how IFN-I affects tissue biology. Recent support for a pathogenic role came from a study depleting plasmacytoid dendritic cells during bleomycin-induced skin fibrosis. The depletion reduced the bleomycin-induced IFN-I-stimulated transcripts and both prevented and reversed fibrosis. Additionally, two recent articles, one identifying SSc endothelial cell injury markers and one showing repressed IFN signaling in SSc keratinocytes, suggest the possibility of unbalanced IFN-I activities on distinct cells types.
SUMMARY: Recent results support a pathogenic role for IFN-I in skin fibrosis, and recent studies along with others suggest a scenario whereby SSc skin damage results from too much IFN-I-activity driving vasculopathy in combination with too little IFN-I-mediated epidermal integrity and antifibrotic fibroblast phenotype.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31436583     DOI: 10.1097/BOR.0000000000000659

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  6 in total

1.  Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma.

Authors:  Rebecca L Ross; Clarissa Corinaldesi; Gemma Migneco; Ian M Carr; Agne Antanaviciute; Christopher W Wasson; Antonio Carriero; Jörg H W Distler; Steve Holmes; Yasser M El-Sherbiny; Clive S McKimmie; Francesco Del Galdo
Journal:  Ann Rheum Dis       Date:  2021-02-04       Impact factor: 19.103

2.  Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib.

Authors:  Samuel Hidalgo-Ríos; Jaime Carrillo-García; David S Moura; Silvia Stacchiotti; Antonio López-Pousa; Andrés Redondo; Antoine Italiano; Antonio Gutiérrez; Giovanni Grignani; Nadia Hindi; José-Antonio López-Guerrero; Xavier García Del Muro; Javier Martínez Trufero; Emanuela Palmerini; Ana Sebio García; Daniel Bernabeu; Axel Le Cesne; Paolo Giovanni Casali; Jean-Yves Blay; Josefina Cruz Jurado; Javier Martin-Broto
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

3.  Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.

Authors:  Dinesh Khanna; Cristina Padilla; Lam C Tsoi; Vivek Nagaraja; Puja P Khanna; Tracy Tabib; J Michelle Kahlenberg; Amber Young; Suiyuan Huang; Johann E Gudjonsson; David A Fox; Robert Lafyatis
Journal:  JCI Insight       Date:  2022-09-08

Review 4.  Immune Cell-Stromal Circuitry in Lupus Photosensitivity.

Authors:  Ji Hyun Sim; William G Ambler; Isabel F Sollohub; Mir J Howlader; Thomas M Li; Henry J Lee; Theresa T Lu
Journal:  J Immunol       Date:  2021-01-15       Impact factor: 5.422

5.  Noncytotoxic Inhibition of the Immunoproteasome Regulates Human Immune Cells In Vitro and Suppresses Cutaneous Inflammation in the Mouse.

Authors:  Marie Dominique Ah Kioon; Michael Pierides; Tania Pannellini; Gang Lin; Carl F Nathan; Franck J Barrat
Journal:  J Immunol       Date:  2021-03-05       Impact factor: 5.422

Review 6.  Novel insights into dendritic cells in the pathogenesis of systemic sclerosis.

Authors:  T Carvalheiro; M Zimmermann; T R D J Radstake; W Marut
Journal:  Clin Exp Immunol       Date:  2020-02-13       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.